Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study-Reference-Cited by-同舟云学术

Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study

Published:2021-10-05 Issue: Volume: Page:
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Saito Takuya¹,Hyodo Yohei²,Sakaguchi Reiko²,Nakamura Hiroshi²^ORCID,Ishigooka Jun³

Affiliation:

1. Department of Child and Adolescent Psychiatry, Hokkaido University Hospital, Sapporo, Japan.

2. Sumitomo Dainippon Pharma Co., Ltd., Chuo-Ku, Tokyo, Japan.

3. Institute of CNS Pharmacology, Shibuya-ku, Tokyo, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/cap.2021.0058

Reference31 articles.

1. Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Edn., Text Revision. Washington, DC; American Psychiatric Association, 2000.

3. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

4. Developments in Pediatric Psychopharmacology

5. Blonanserin

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of adolescent lactation due to the drug blonanserin;2024-08-05

2. Temporal trends in antipsychotic prescriptions for pediatric patients using an administrative hospital database in Japan: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2024-01-02

3. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials;BMC Psychiatry;2023-10-11

4. Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance;The European Journal of Psychiatry;2023-10